Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
6-month extension trial of asenapine versus olanzapine in schizophrenia with predominant persistent negative symptoms
2005-002169-35Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of asenapine and olanzapine in schizophrenia (2 arms), sponsored by Organon & Co. Primary endpoint: Change in Negative Symptom Assessment total score. Started Oct 2005; status: completed.
02
Drugs
asenapineolanzapine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2005-002169-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002169-35.